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Abstract Acute ischemic stroke affects over 800,000 US
adults annually, with hundreds of thousands more
experiencing a transient ischemic attack. Emergent evaluation, prompt acute treatment, and identification of stroke
or TIA (transient ischemic attack) etiology for specific
secondary prevention are critical for decreasing further
morbidity and mortality of cerebrovascular disease. The
Biomarkers of Acute Stroke Etiology (BASE) study is a
multicenter observational study to identify serum markers
defining the etiology of acute ischemic stroke.
Observational trial of patients presenting to the hospital
within 24 h of stroke onset. Blood samples are collected
at arrival, 24, and 48 h later, and RNA gene expression is
utilized to identify stroke etiology marker candidates. The
BASE study began January 2014. At the time of writing,
there are 22 recruiting sites. Enrollment is ongoing, expected to hit 1000 patients by March 2017. The BASE
study could potentially aid in focusing the initial diagnostic evaluation to determine stroke etiology, with more rapidly initiated targeted evaluations and secondary prevention strategies.

Clinical Trial Registration
Clinicaltrials.gov NCT02014896 https://clinicaltrials.gov/
ct2/show/NCT02014896?term=biomarkers+of+acute+
stroke+etiology&rank=1
Keywords Acute Stroke . RNA expression . Biomarkers

Introduction
Acute ischemic stroke (AIS) remains a leading cause of mortality and morbidity in the USA, affecting over 800,000 adults
annually and leaving many with permanent disability [1].
Furthermore, hundreds of thousands of Americans experience
a transient ischemic attack which often precedes a major
stroke and serves as a warning for future ischemic events
[2]. Despite resolved symptoms, experiencing a TIA (transient
ischemic attack) is associated with a stroke risk of up to 20%
within 90 days. Collectively, previous stroke and TIA confer
an annual recurrent stroke risk of 3–4% [1]. Emergent evaluation, prompt acute treatment, and identification of stroke or
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TIA etiology for specific secondary prevention are critical for
decreasing further morbidity and mortality of cerebrovascular
disease [2].
Key to secondary prevention is stroke etiology identification.
This is because the stroke etiology determines which treatment is
most effective to prevent future strokes. In addition to risk factor
modification for all patients with stroke or TIA, anticoagulant
therapy is indicated for cardioembolic stroke. This is in contradistinction to atherogenic strokes where antiplatelet agents are
recommended. Currently, the diagnosis of ischemic stroke etiology is determined from a combination of patient history, clinical
assessment, cerebrovascular imaging, and cardiovascular evaluation. However, even with extensive testing, identifying the
cause of an acute stroke is challenging. Strokes of unclear etiology, or cryptogenic strokes, represent a significant risk as optimal
prevention measures cannot be identified. Therefore, there is a
great need to identify the pathogenesis of acute ischemic stroke in
order to implement targeted and effective preventative measures.
Recent studies have suggested whole blood RNA expression
may help differentiate ischemic stroke mechanisms [3–7].The
Biomarkers of Acute Stroke Etiology (BASE) study
(NCT02014896) is a multicenter observational study utilizing
RNA gene expression to identify the etiology of acute ischemic
stroke. When a stroke or TIA occurs, the immune system changes gene expression in multiple cell types, thus activating innate
and adaptive immune responses. Previous studies suggest that
differential gene expression profiles are a function of stroke subtype, [3–7] with each subtype producing a unique gene expression “signature”. The Ischemia Care diagnostic platform consists
of whole blood biomarker tests to determine the etiology of
ischemic stroke (ISCDX, Blue Ash, OH) by measuring acute
ischemic stroke gene expression changes. For example, the
ISCDX test distinguishes between cardioembolic and large artery, as well as lacunar, atherosclerotic stroke using a signature of
40 unique genes. A patient’s pattern of gene regulation can determine if the stroke etiology is that of a cardioembolic or large
artery atherosclerotic source. Further, a separate 37 gene signature can differentiate cardioembolic strokes caused by atrial fibrillation (AF) or other cardioembolic sources. Ultimately, for
most patients, the diagnostic expression pattern clearly identifies
stroke etiology.
The primary objective of the BASE study is to confirm the
diagnostic accuracy of the ISCDX test to identify stroke subtypes
in patients with acute ischemic stroke. This manuscript describes
the methodology employed in the BASE study to identify stroke
etiology in patients presenting with acute stroke.

Methods
BASE is an ongoing prospective multicenter convenience
sample study, registered as NCT02014896 and approved by
each participating Institutional Review Board. Patients with
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acute ischemic stroke who meet the inclusion and exclusion
criteria (Table 1) are enrolled in the Emergency Department
(ED) and blood samples are drawn. Control samples consist of
100 non-stroke ED patients matched on clinical risk factors of
age, race, gender, smoking history, diabetes, hypertension,
atrial fibrillation, and hyperlipidemia.
BASE initially enrolled acute stroke patients within 8 h of
symptom onset or the time of last known to be normal.
However, after patient enrollment reached 650, evaluation
time was lengthened to 24 (+/−6) hours. This was from a
planned interim data analysis determining the 24 (+/−6) hour
window from symptom onset was most predictive for identifying stroke cause using blood biomarkers, was most consistent with the time a stroke patient would present, and represented the window for which a blood test for stroke would be
used clinically.
Typically, prior to enrollment, patients are evaluated by the
local stroke team or ED physicians, have undergone baseline
laboratory testing and cerebrovascular imaging, and may receive
intravenous thrombolysis and/or endovascular therapies.
Approximately 2.5 mL of blood is drawn into two
PreAnalytiX® PAXgene® blood RNA tubes (Qiagen) within
24 (+/−6) hours of stroke onset. Additional draws occur at 24
(+/− 6), and 48 h (+/− 6), or at ED/hospital discharge, whichever
comes first. Longer collection periods were considered but were
challenged by the amount of RNA response making it difficult to
identify diagnostic patterns consistent with the primary objective
of this study. Eligible control subjects are patients presenting
without a potentially neurologic complaint and have blood drawn
within 6 h of ED presentation.
PAXgene tubes can be kept at room temperature for up to
24 h, and then are frozen at −20 °C, until shipped on dry ice to
the Ischemia Care CLIA laboratory (Blue Ash, OH) where the
ISCDX testing is performed. The entire sample from one tube
Table 1

Inclusion and exclusion criteria

Inclusion criteria
Suspected acute ischemic stroke within 24 (+/− 6) hours of symptom
onset
Baseline CT normal, without hemorrhage or alternate explanation for
symptoms
>18 years old
Informed consent obtained
Exclusion criteria
Central nervous system infection within 30 days
Serious head trauma within 30 days
Any stroke within 30 days
Active cancer (not in remission)
Autoimmune disease (e.g., lupus)
Acute systemic infection
Major surgery within 90 days
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will be used to perform the ISCDX test. The second tube is stored
at −80 °C for future testing.
Analysis for RNA expression is performed by Affymetrix®
human gene ST array plates. These provide whole-genome coverage, including protein coding and long intergenic non-coding
RNA (lincRNA) transcripts. Whole genome arrays thus have the
ability to provide a complete profile of mRNA expression. The
microarray procedure is performed as follows:
1) RNA extraction: Total RNA is extracted from blood collected in PAXgene RNA tubes which are used to specifically preserve the integrity of the RNA.
2) cDNA synthesis and labeling: Multiple complementary
DNA (cDNA) copies are made of each RNA. cDNAs
are fragmented to sizes for optimal hybridization to the
probes on the microarrays and labeled so they can be
stained and detected after hybridization to the microarray.
3) Microarray hybridization: Amplified, fragmented and labeled cDNAs are hybridized overnight to an Affymetrix
U133 plus 2.0 microarray. Each microarray contains
probes for the majority of expressed RNAs from the human genome.
4) Microarray staining and scanning: After hybridization, each
microarray is washed, stained with fluorescence that binds to
the labels previously attached to each cDNA, then rinsed.
Each microarray is then scanned with a laser to record the
level of expression of each probe on the array.
5) Microarray data is normalized using the “Signal Space
Transformation with probe Guanine Cytosine Count
Correction” algorithm (ThermoFisher, Waltham, MA) to
control for normal experimental variability. Array quality
control metrics are checked against acceptable ranges and
rejected when not within range. As an additional quality
check, sex-specific expressed genes are checked against
the clinically recorded sex to identify potential sample
mix-ups.
All study patients undergo standard clinical assessments, with
baseline biochemistry and neuroimaging as standard of care for
acute stroke. Vascular imaging is not required before enrollment.
Control patients do not receive specified imaging or biochemistry
assays as part of the study protocol. The diagnostic evaluation is
per standard of care and is up to the physician team caring for the
patient. In the USA, this generally consists of a 12-lead ECG,
bedside ECG monitoring, standard transthoracic echocardiogram
(or transesophageal echocardiogram as indicated), and outpatient
cardiac event monitoring (the duration of which is determined by
the physician of record).
Specific study purpose data include demographics, past
medical history, social history, medications, ED evaluation
information (including the National Institutes of Health stroke
scale), neurologic symptom duration and onset time, baseline
cerebrovascular imaging, laboratory tests, electrocardiogram,
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and cardiac monitoring. Most acute ischemic strokes are admitted per local protocol and receive care per local treating
physicians. Cardiac evaluations during admission are collected, as will data of any other therapy or studies performed to
treat or determine stroke etiology.
Ischemic stroke etiology is determined locally using all
sources of clinical information, according to the Trial of
Org 10172 in Acute Stroke Treatment (TOAST) classification (Table 2) [8]. TOAST, (Table 2), is a well validated
classification system with 5 subtypes of ischemic stroke.
A cardioembolic stroke diagnosis requires at least one
source of cardiac emboli and the exclusion of large or
small vessel causes of stroke. Cardioembolic sources include AF, acute myocardial infarction, prosthetic valves,
and/or cardiomyopathy. Patients with AF are identified
using electrocardiogram, echocardiogram, and cardiac
monitoring. Cardiac monitoring is performed as standard
of care (either during hospitalization or using outpatient
event monitoring in unconfirmed suspected AF).
The diagnosis of large-vessel stroke requires >50% stenosis of ipsilateral extracranial or major intracranial artery (middle cerebral artery, posterior cerebral artery, basilar artery)
presumed due to atherosclerosis determined by ultrasound,
computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography, and is further
supported by the absence of acute infarction in other vascular
territories. Because of a lack of standardization for defining
stroke in the setting of ulcerated plaques of less than <50%
narrowing, sites were not asked to categorize these, rather they
are placed in the cryptogenic category.
The diagnosis of small-vessel stroke requires symptoms
corresponding to a subcortical infarction <15 mm in longest
diameter on brain imaging, typically identified on MRI, and
the exclusion of other stroke mechanisms. Often, patients will
present with classic lacunar syndromes (pure motor
hemiparesis). Stroke caused by other uncommon etiologies
refers to atypical but specific causes of ischemic stroke (e.g.,
nonatherosclerotic arteriopathies, vascular dissections, or hypercoagulable states).

Table 2

Subtype of ischemic strokes, TOAST classification

Stroke subtype
Large artery atherosclerosis
Cardioembolic
Small-vessel occlusion (lacune)
Stroke of other determined etiology
Stroke of undetermined etiology
(cryptogenic)

Recommended treatment
Antiplatelet therapy
Anticoagulation therapy
Blood pressure control
Therapy should be specific
to cause
Aspirin therapy

TOAST Trial of Org 10172 in Acute Stroke Treatment
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Finally, strokes with an extensive work up and remaining
of unknown origin are referred to as cryptogenic, patients with
multiple stroke etiologies identified are placed in their own
category, and those with insufficient information are categorized as such.
The final gold standard diagnosis is determined by an adjudication committee, blinded to ICDX testing results, and
consisting of two vascular neurologists independently
reviewing all available data. All diagnostic impression data
will be used for the TOAST criteria. In cases of unresolved
diagnostic disagreement, a third vascular neurologist will
serve as a tie breaker.
The BASE study is non-interventional, with treating physicians blinded to genomic test results, thus presenting minimal to no patient risk. Categorical data will be analyzed by
chi-square testing and linear continuous data by student’s t
test. Univariate analysis will identify significant outcome predictors for multivariable modeling. RNA expression data will
be presented as heat maps with multiple comparison corrections. Statistical performance of cut points, determined by
multivariable modeling and by heat map identification, will
be presented using sensitivity, specificity, and C statistic, as
well as positive and negative predictive values and likelihood
ratios. Net reclassification improvement and integrated discrimination improvement will evaluate the change in clinical
diagnosis using RNA expression.
The robust BASE trial methodology is predicted to allow
for the generation of a number of RNA expression signatures
that will be of clinical significance. First will be differentiating
between strokes resulting from embolic causes, as compared
to stroke caused by large artery thrombosis. This important
determination dichotomizes treatment strategies into the divergent categories of either anticoagulants or antiplatelet medication. Secondly, RNA expression signatures are likely to
separate true stroke presentations from that of stroke mimic.
As a point of care test, this distinction would have massive
health care economic benefits as the current standard results in
patients suffering from stroke mimics receive expensive, complicated, and unnecessary evaluations that are ultimately negative. A third potential outcome from the BASE trial is that of
determining the “last known normal status”. Per current
guidelines, the administration of lytic therapy requires a confirmed stroke onset of less than 4.5 h. In all patients, awakening from sleep, the “last known normal” parameter is unknown. This results in 80% of patients with acute stroke not
being able to receive life-saving lytic therapy. It is anticipated
that the RNA expression signature will identify the time of
stroke onset, and if developed as a point of care test, could
provide the opportunity for many more patients to receive
therapy for their acute stroke presentation.
As is the case with all investigations, the potential for
methodologic limitations may exist. Because the medical care
in patients enrolled in BASE is determined by the physician
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caring for the patient, and not by a defined protocol, variations
in stroke etiology evaluation may occur (e.g., not all patients
may receive echocardiographic bubble studies), and how this
may impact outcomes will be unmeasured. Furthermore, the
timing of RNA expression measurement was arbitrarily chosen at 24 h as this is a time for which marker analysis is
obtainable and is still within a clinically relevant window.
Arguments for alternative timing could be effected and may
provide impetus for future investigations. Finally, the decision
to define a vascular stenosis <50% to be more likely associated with embolic events represents a compromise for consistent
diagnosis, but may ultimately not be definitive in its accuracy.
BASE is funded by Ischemic Care, Inc., whose involvement includes providing funding for blood and data collection, assay performance, gold standard diagnostic adjudication, and statistical analysis.

Summary
The BASE study began January 2014. At the time of writing
there are 22 recruiting sites. Enrollment is on target, expected
to include 1000 patients by March 2017. Results from the
BASE trial will result in the identification of a series of unique
stroke biomarkers. It is anticipated that the identification of
stroke etiology will be possible, thus differentiating large artery atherogenic events from stroke caused by emboli.
Because this determination is not currently possible, it is estimated that the 250,000 annual US stroke patients whose
stroke etiology is unknown, may benefit.
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